case_images: PMC6378798_01
case_images: Trend in calcium level during the course of treatment with patiromer acetate.
case_images: CRIN2019-3507407.001.jpg
case_images: PMC6378798_01_CRIN2019-3507407.001.jpg
case_images: fig1
case_images: On follow-up after an additional 30 days, calcium returned even higher, 11.6 mg/dL (Figure 1), and potassium even lower, 4.6 mmol/L (Figures 2 and 3).
case_images: Trend in potassium level during the course of treatment with patiromer acetate.
case_images: CRIN2019-3507407.002.jpg
case_images: PMC6378798_01_CRIN2019-3507407.002.jpg
case_images: fig2
case_images: On follow-up after an additional 30 days, calcium returned even higher, 11.6 mg/dL (Figure 1), and potassium even lower, 4.6 mmol/L (Figures 2 and 3).
case_images: Trend in calcium and potassium level during the course of treatment with patiromer acetate. Arrows indicate start and stop date of patiromer acetate.
case_images: CRIN2019-3507407.003.jpg
case_images: PMC6378798_01_CRIN2019-3507407.003.jpg
case_images: fig3
case_images: On follow-up after an additional 30 days, calcium returned even higher, 11.6 mg/dL (Figure 1), and potassium even lower, 4.6 mmol/L (Figures 2 and 3).